Neuropace Inc (NPCE) Inventory Turnover Ratio, from second quarter 2026 to second quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
Neuropace Inc   (NASDAQ: NPCE)
 

Neuropace Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Due to inventory build up in the second quarter 2026, Neuropace Inc 's inventory turnover ratio sequentially decreased to 1.14 in the second quarter 2026, unsurprisingly, as the Neuropace Inc markets continue to deteriorate, and NPCE's faces growing challenges to bring down its inventories. Neuropace Inc 's average inventory processing period in the Jun 30 2026 quarter, has increased to 320 days, from 297 days, in the Mar 31 2026 quarter.

Within Healthcare sector 298 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 1636 in the first quarter 2026, to 1778.

NPCE Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Neuropace Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NPCE Inventory Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Inventory Growth 10.8 % 22.93 % 26.27 % 50.07 % 43.85 %
Y / Y Cost of Sales Growth -21.6 % -20 % 0 % 20 % 0 %
Inventory Turnover Ratio (TTM) 1.14 1.23 1.35 1.43 1.52
NPCE's Total Ranking # 1778 # 1636 # 1326 # 1089 # 1301
Average inventory processing period 320 296 269 255 241
Seq. Inventory Growth 8.49 % -1.2 % -6.83 % 10.94 % 20.37 %
Seq. Cost of Sales Growth -2 % -33.33 % 0 % 20 % 0 %




Inventory Turnover Ratio Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 138
Healthcare Sector # 299
Overall Market # 1778

Inventory Turnover Ratio Statistics
High Average Low
1.67 1.51 1.14
(Mar 31 2025)   (Jun 30 2026)



NPCE Company Profile >> Back to NPCE Efficiency Comparisons >> Compare NPCE Inventory Turnover Ratio to its Competitors

Financial Statements
Neuropace Inc 's Inventories $ 18 Millions Visit NPCE's Balance sheet
Neuropace Inc 's Cost of Revenues TTM $ 20 Millions Visit NPCE's Income Statement
What are NPCE's Sales? Visit NPCE's Sales by Segment

Other Inventory Turnover Ratios
Neuropace Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Medical Equipment & Supplies Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
NPCE's Inventory Turnover Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for NPCE's Competitors
Inventory Turnover Ratio for NPCE's Suppliers
Inventory Turnover Ratio for NPCE's Customers

You may also want to know
NPCE's Sales Growth Rates NPCE's Pe Price to earnings ratio NPCE's Receivables Turnover Ratio NPCE's Stock Quote
NPCE's Net Income Growth Rates NPCE's Ps Price to Sales ratio NPCE's Sales per Employee NPCE's Asset Turnover Ratio
NPCE's Net Margin NPCE's Pb Price to Book ratio NPCE's Financial Strength Ratios NPCE's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Jun 30 2026 Inventories at quarter ending Jun 30 2026
Revvity Inc  2.98 $ 1,136.473  Millions$ 381  Millions
Amneal Pharmaceuticals Inc   2.98 $ 1,891.689  Millions$ 635  Millions
Resmed Inc   2.97 $ 2,770.562  Millions$ 933  Millions
Msa Safety Inc  2.92 $ 1,021.036  Millions$ 350  Millions
Ligand Pharmaceuticals Incorporated  2.91 $ 32.387  Millions$ 11  Millions
Logicmark Inc  2.83 $ 3.881  Millions$ 1  Millions
Merck and Co Inc   2.79 $ 17,996.000  Millions$ 6,447  Millions
Inspiremd Inc   2.78 $ 8.847  Millions$ 3  Millions
Ani Pharmaceuticals Inc  2.69 $ 387.398  Millions$ 144  Millions
International Stem Cell Corporation  2.61 $ 4.285  Millions$ 2  Millions
Biomerica Inc   2.59 $ 4.091  Millions$ 2  Millions
Evofem Biosciences Inc   2.58 $ 4.418  Millions$ 2  Millions
Nephros Inc   2.54 $ 8.991  Millions$ 4  Millions
Illumina Inc   2.52 $ 1,510.000  Millions$ 599  Millions
IMPACT BIOMEDICAL INC.  2.46 $ 0.414  Millions$ 0  Millions
Quidelortho Corp  2.45 $ 1,481.500  Millions$ 605  Millions
Pro dex Inc   2.43 $ 53.213  Millions$ 22  Millions
Angiodynamics Inc   2.43 $ 142.834  Millions$ 59  Millions
Journey Medical Corp  2.42 $ 23.556  Millions$ 10  Millions
Aquestive Therapeutics Inc   2.42 $ 17.828  Millions$ 7  Millions
Cannapharmarx Inc   2.37 $ 2.483  Millions$ 1  Millions
Fortress Biotech Inc   2.34 $ 22.768  Millions$ 10  Millions
Scientific Industries Inc   2.33 $ 4.057  Millions$ 2  Millions
Insight Molecular Diagnostics Inc   2.31 $ 0.868  Millions$ 0  Millions
Sanara Medtech Inc   2.29 $ 7.981  Millions$ 3  Millions
China Pharma Holdings Inc  2.25 $ 3.450  Millions$ 2  Millions
Beta Bionics Inc   2.23 $ 50.111  Millions$ 22  Millions
Medtronic Plc  2.21 $ 13,136.000  Millions$ 5,950  Millions
Embecta Corp   2.19 $ 418.400  Millions$ 191  Millions
Avita Medical Inc   2.18 $ 13.950  Millions$ 6  Millions

Date modified: 2026-09-04T10:33:25+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.